iShares Microcap ETF (IWC)

The company announced an agreement to be acquired by Royal Cup Coffee & Tea in an all-cash deal valued at $1.29 per share.

The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform.

Brokerages cut the stock’s price target after the company reported a 38% decline in fourth-quarter revenue.

The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

KORE stated that Searchlight and Abry will acquire all shares of the company’s issued and outstanding common stock that they currently don’t own in an all-cash transaction valued at nearly $726 million.

The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

Cipher’s fourth-quarter revenue came in at $60 million, significantly below the consensus estimates of $85.7 million, according to Fiscal.ai data.

The biotech company reported statistically significant Phase 3 data for QTORIN gel.

The company announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share.

The company said that it has filed a third-party, independent Technical Report updating its Mineral Resource estimate with an effective date of January 21, 2026.

The company said it expects $115 million to $120 million in revenue for fiscal year 2027, however analysts on average were expecting the revenue of $85.23 million, as per data from fiscal.ai.

The company announced the acquisition of ad-tech firm IndiCue for up to $40 million in total consideration.

The company announced pricing for a $12 million public offering at an 8% discount to Thursday’s close.

The company said that it will continue to seek funding for the SER-155 Phase 2 study.

The company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.

The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration.

The company signed an agreement with a major U.S. defense prime contractor to supply a subsystem that supports missile propulsion.

The company received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.

The company announced that it has decided to cease clinical development of its lead asset dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP).

The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease.

The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.